NEW YORK (GenomeWeb News) – Exiqon today announced it has granted a non-exclusive license for its locked nucleic acids technology to Becton Dickinson for the development of diagnostics for infectious diseases.
Under the terms of the deal, Exiqon will receive upfront and milestone payments and royalties on global sales of products stemming from the agreement. No other financial terms were disclosed.